Adverse event | Famitinib alone | Famitinib with CCRT | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Grade 1–2 | Grade 3 | Grade 4 | Grade 5 | Total | Grade 1–2 | Grade 3 | Grade 4 | Grade 5 | Total | |
Leukopenia | 1 (5%) | 0 | 0 | 0 | 1 (5%) | 2 (10%) | 17 (85%) | 1 (5%) | 0 | 20 (100%) |
Neutropenia | 1 (5%) | 0 | 0 | 0 | 1 (5%) | 9 (45%) | 10 (50%) | 1 (5%) | 0 | 20 (100%) |
Anaemia | 2 (10%) | 0 | 0 | 0 | 2 (10%) | 16 (80%) | 4 (20%) | 0 | 0 | 20 (100%) |
Radiation mucositis | 0 | 0 | 0 | 0 | 0 | 16 (80%) | 3 (15%) | 1 (5%) | 0 | 20 (100%) |
Nausea and vomiting | 0 | 0 | 0 | 0 | 0 | 16 (80%) | 1 (5%) | 0 | 0 | 17 (85%) |
Radiation dermatitis | 0 | 0 | 0 | 0 | 0 | 13 (65%) | 0 | 0 | 0 | 13 (65%) |
Weight loss | 0 | 0 | 0 | 0 | 0 | 15 (75%) | 0 | 0 | 0 | 15 (75%) |
Proteinuria | 1 (5%) | 0 | 0 | 0 | 1 (5%) | 15 (75%) | 1 (5%) | 0 | 0 | 16 (80%) |
Thrombopenia | 0 | 0 | 0 | 0 | 0 | 10 (50%) | 3 (15%) | 1 (5%) | 0 | 14 (70%) |
Hypertension | 3 (15%) | 0 | 0 | 0 | 3 (15%) | 8 (40%) | 1 (5%) | 0 | 0 | 9 (45%) |
Liver function impairment | 3 (15%) | 0 | 0 | 0 | 3 (15%) | 10 (50%) | 1 (5%) | 0 | 0 | 11 (55%) |
Hypertriglyceridemia | 5 (25%) | 0 | 0 | 0 | 5 (25%) | 5 (25%) | 0 | 0 | 0 | 5 (25%) |
Hearing impairment | 0 | 0 | 0 | 0 | 0 | 4 (20%) | 0 | 0 | 0 | 4 (20%) |
Renal impairment | 0 | 0 | 0 | 0 | 0 | 4 (20%) | 0 | 0 | 0 | 4 (20%) |
Hematuria | 2 (10%) | 1 (5%) | 0 | 0 | 3 (15%) | 4 (20%) | 1 (5%) | 0 | 0 | 5 (25%) |
Haemorrhage | 0 | 0 | 0 | 0 | 0 | 2 (10%) | 0 | 0 | 0 | 2 (10%) |
Skin rash | 2 (10%) | 0 | 0 | 0 | 2 (10%) | 1 (5%) | 0 | 0 | 0 | 1 (5%) |
Hypothyroidism | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Hypercholesterolemia | 1 (5%) | 0 | 0 | 0 | 1 (5%) | 0 | 0 | 0 | 0 | 0 |
Elevated total bilirubin | 1 (5%) | 0 | 0 | 0 | 1 (5%) | 1 (5%) | 0 | 0 | 0 | 1 (5%) |
Elevated GGT | 2 (10%) | 0 | 0 | 0 | 2 (10%) | 2 (10%) | 0 | 0 | 0 | 2 (10%) |